RTW Biotech Opportunities has delivered healthy net asset value growth over the past year, helped by a wave of biotechnology takeovers, while Buybacks have helped narrow the discount to its portfolio value.
RTW Biotech Opportunities (LSE:RTW), the FTSE 250 Investment company managed by New York-based RTW Investments, has been one of the clearer beneficiaries of the recovery in biotechnology markets. Its July 2026 factsheet, the most recent monthly update reviewed, showed a fund whose Net Asset Value (NAV) has risen sharply over twelve months and whose shares now trade at a significantly smaller discount than a year earlier.
Solid twelve-month returns
At the end of July, RTW reported a NAV per share of $2.82. Although the NAV fell 1.6% during the month, as biotech stocks gave back some of their June gains, the year-to-date return stood at 14.7% and the one-year return at 53.6%. Since its launch in October 2019, the fund has delivered a compound annual NAV return of 15.3%.
The share price stood at $2.47, a discount of 12.3% to NAV. That compares with a discount of 28.9% twelve months earlier, a substantial re-rating that reflects both improved sentiment towards the sector and the company's own Capital management. Over the past year, RTW repurchased 7.7 million shares, returning around $14.7m to shareholders.
Portfolio built around clinical catalysts
RTW invests across both public and private biotechnology companies, with a focus on businesses developing innovative therapies. Its largest positions at the end of July were identified by their lead drugs. The top holding, representing 7.4% of NAV, was cretostimogene, a bladder cancer treatment, followed by Zusduri at 7.2% and ORKA-001, a psoriasis candidate, at 5.7%. Vyvgart, a myasthenia gravis drug, made up 5.3%, and the obesity programmes CX11 and ribupatide accounted for 5.0% and 4.6% respectively.
The portfolio also includes companies created by RTW itself. In July, Yarrow Bioscience, the seventh company formed by the manager, completed a Merger with VYNE Therapeutics and began trading on Nasdaq under the ticker YARW. RTW said it achieved a multiple of 3.7 times its invested capital on the deal, with shares rising 192% on their first day of trading, a gain equivalent to about $20.4m, or 2.0% of the June NAV.
M&A boom supports the sector
A key driver of the improvement in biotech sentiment has been the pace of mergers and acquisitions. The manager noted that Vertex's roughly $10bn agreement to acquire Crinetics was the third transaction of $10bn or more this year, and that year-to-date deal value had reached about $105bn. Large pharmaceutical companies facing Patent expiries on major products have been active buyers of mid-sized biotech groups, which tends to lift valuations across the sector.
July itself was a weaker month, with US biotech benchmarks falling between roughly 4% and 7%, illustrating the Volatility inherent in the asset class. Even so, the longer-term figures show how quickly sentiment towards the sector has improved since the lows of recent years.
What to watch
The fund's prospects remain closely tied to clinical trial readouts, regulatory decisions and further Takeover activity in the sector. Investors will also monitor whether the discount continues to narrow, and how actively the board pursues buybacks if it widens again. RTW publishes monthly valuation updates, and its next quarterly letter will provide further detail on portfolio positioning.



_11_18_2026_06_43_20_247880.jpg)


Please wait processing your request...